Opus Genetics, Inc.

IRD Healthcare Biotechnology

Opus Genetics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.2 million, up 29.1% from fiscal 2024. In the quarter to June 2026, revenue fell 73.8%, EPS grew 33.3% and free cash flow fell 16.4%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

3.81 0.24 −5.93%
Market cap
$336.9M
P/E
0.0×
Fwd P/E
−3.8×
Dividend yield
—
F-score
5/9
Altman Z
−4.35
Beneish M
−4.00
Dividend safety
n/a

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Older periods Sep '25 Dec '25 Mar '26 Jun '26
Total current assets
35.91 50.04 66.60 92.70
Total non-current assets
0.21 0.20 0.19 0.27
Total Assets
36.12 50.24 66.79 92.97
Total current liabilities
29.09 7.78 9.34 7.61
Total non-current liabilities
1.07 27.11 103.28 98.35
Total liabilities
30.16 34.90 112.62 105.95
Common Equity (Total)
5.97 15.35 (45.84) (12.99)
Shareholders Equity (Total)
5.97 15.35 (45.84) (12.99)
Total Debt
1.07 — — 34.93

Show all line items

In millions of $ except per-share values · columns are period end dates